Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial - 04/04/13
, William D Tap, MD a, Li-Xuan Qin, PhD b, Michael B Livingston, ProfMD e, Samir D Undevia, MD f, Bartosz Chmielowski, MD g, Mark Agulnik, MD h, Scott M Schuetze, MD i, Damon R Reed, MD j, Scott H Okuno, ProfMD k, Joseph A Ludwig, MD l, Vicki Keedy, MD m, Petra Rietschel, MD n, Andrew S Kraft, ProfMD o, Douglas Adkins, ProfMD p, Brian A Van Tine, MD p, Bruce Brockstein, MD h, Vincent Yim, BA a, Christiana Bitas, BA a, Abdul Abdullah, BA a, Cristina R Antonescu, ProfMD c, Mercedes Condy, RN d, Mark A Dickson, MD a, Shyamprasad Deraje Vasudeva, MA a, Alan L Ho, MD a, L Austin Doyle, ProfMD q, Helen X Chen, ProfMD q, Robert G Maki, ProfMD rSummary |
Background |
Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. The expression of IGF-1R seems to be crucial for this effect. We investigated the safety and efficacy of the combination of the IGF-1R antibody cixutumumab and the mTOR inhibitor temsirolimus in patients with chemotherapy-refractory bone and soft-tissue sarcomas according to IGF-1R expression by immunohistochemistry.
Methods |
We undertook a multicentre, open-label, phase 2 study in 19 cancer centres in the USA. Patients aged at least 16 years with a histologically confirmed diagnosis of bone or soft-tissue sarcoma were allocated on the basis of IGF-1R expression by immunohistochemistry to one of three treatment groups: IGF-1R-positive soft-tissue sarcoma (group A), IGF-1R-positive bone sarcomas (group B), or IGF-1R-negative bone and soft-tissue sarcoma (group C). Patients received weekly treatment with cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) in 6-week cycles. A Simon optimal two-stage design was used for every arm. The primary endpoint was progression-free survival (PFS) at 12 weeks by intention-to-treat analysis in the first 54 patients assigned to every treatment arm. Although patients still remain on treatment, this trial has completed enrolment and this represents the final analysis. This study is registered with ClinicalTrials.gov, number NCT01016015.
Findings |
Between Nov 18, 2009, and April 11, 2012, 388 patients were screened for IGF-1R expression and 54 were assigned to each arm. 17 of 54 patients in the IGF-1R-positive soft-tissue sarcoma group (31%; one-sided 95% CI lower bound 21%; two-sided 90% CI 21–43), 19 of 54 in IGF-1R-positive bone sarcoma group (35%; one-sided 95% CI lower bound 24%; two-sided 90% CI 24–47), and 21 of 54 in the IGF-1R-negative group (39%, one-sided 95% CI lower bound 28%; two-sided 90% CI 28–51) were progression free at 12 weeks. On April 6, 2011, the protocol was amended to include three additional patients in the IGF-1R-positive soft-tissue sarcoma group (total of 57 patients) and nine more in the IGF-1R-negative group (total of 63 patients). There were 2546 adverse events reported during the study, 214 (8%) of which were grade 3–4. The most common grade 3–4 toxicities in the 174 treated patients were anaemia in 16 (9%) patients, hyperglycaemia in 18 (10%), hypophosphataemia in 16 (9%), lymphopenia in 25 (14%), oral mucositis in 19 (11%), and thrombocytopenia in 19 (11%).
Interpretation |
The combination of cixutumumab and temsirolimus shows clinical activity in patients with sarcoma and forms a basis for future trials. However, IGF-1R expression by immunohistochemistry is not predictive of clinical outcome after treatment with this combination.
Funding |
National Cancer Institute and CycleforSurvival Fund, Memorial Sloan-Kettering Cancer Center.
Le texte complet de cet article est disponible en PDF.Plan
Vol 14 - N° 4
P. 371-382 - avril 2013 Retour au numéro
Article précédent
- Breast-cancer screening with trained volunteers in a rural area of Sudan: a pilot study
- Dafalla Omer Abuidris, Ahmed Elsheikh, Majdeldien Ali, Hassan Musa, Elgaili Elgaili, Anas O Ahmed, Imadeldien Sulieman, Sulma Ibrahim Mohammed
- Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer
- Imran O Morhason-Bello, Folakemi Odedina, Timothy R Rebbeck, Joe Harford, Jean-Marie Dangou, Lynette Denny, Isaac F Adewole
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?